ATTO-1310-101 Enrolling

Research Trial for Eczema and Chronic Itch (22 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults aged 18 to 65 years old who have eczema/atopic dermatitis (AD) OR those aged 18 to 85 years old who have chronic pruritis (itch), may be eligible.

 

Inclusion Criteria:

      • Have a body weight of 50 to 125 kg (110 to 275 lbs)
      • Meet one of the following condition categories:

Patients with Atopic Dermatitis:

          • have a clinically confirmed diagnosis of active AD
          • with at least a 1-year history of AD and no significant flares in AD for at least 4 weeks
          • moderate to severe disease is also required

Patients with Chronic Pruritus:

          • have chronic pruritus for at least 6 months and is unresponsive to at least a 2-week course of emollient use before the screening visit
          • chronic pruritus must affect at least 2 of the following areas: legs, arms, or trunk
      • Need to use emollient throughout the study

 

Participant Info:

      • No cost to participate or receive study medication
      • Regular visits with study doctors who are familiar with treating AD and chronic pruritis
      • Will receive investigational injected medication (active study drug) or placebo
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

      • Individuals will be asked to visit the study centre about 12 times over a period of about 22 weeks

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: August 13, 2025

Official Title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus

ClinicalTrials.gov ID

NCT06787586

Sponsor

Attovia Therapeutics Inc

Study Description

  • Brief Summary:

    The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

  • Condition or Disease:

    Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus

  • Intervention/Treatment:

    Drug: ATTO-1310 Drug: ATTO-1310 Placebo Drug: ATTO-1310 Drug: ATTO-1310 Placebo Drug: ATTO-1310 Drug: ATTO-1310 Placebo
  • Phase:

    PHASE 1

  • Ages Eligible for Study:

    18 Years and 85 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content